Suppr超能文献

亲水性和亲脂性β受体阻滞剂的中枢神经系统副作用。

Central nervous system side-effects with hydrophilic and lipophilic beta-blockers.

作者信息

Westerlund A

出版信息

Eur J Clin Pharmacol. 1985;28 Suppl:73-6. doi: 10.1007/BF00543714.

Abstract

Previous investigations have suggested that hydrophilic beta-blockers, which appear at low concentrations in brain tissue, are less likely to produce CNS-related side-effects than are lipophilic beta-blockers, which occur at higher concentrations in the brain. The validity of this hypothesis was tested in a double-blind crossover study in which the hydrophilic beta-blocker atenolol was compared with the lipophilic agents metoprolol and propranolol, in 14 patients with a previous history of nightmares or hallucinations when treated with lipophilic beta-blockers. Nightmares or hallucinations were reported by all patients receiving lipophilic beta-blockers but by only three patients receiving atenolol. The total number of episodes was significantly lower (p less than 0.01) for patients receiving atenolol (8) than for those receiving lipophilic beta-blockers (54). It is concluded that atenolol is significantly less likely to provoke nightmares and hallucinations than are the lipophilic beta-blockers, metoprolol and propranolol. It seems likely that this finding is due to the differences in hydrophilicity amongst these drugs.

摘要

先前的研究表明,亲水性β受体阻滞剂在脑组织中浓度较低,与在脑中浓度较高的脂溶性β受体阻滞剂相比,产生中枢神经系统相关副作用的可能性较小。在一项双盲交叉研究中对这一假设的有效性进行了检验,该研究将亲水性β受体阻滞剂阿替洛尔与脂溶性药物美托洛尔和普萘洛尔进行比较,研究对象为14名既往使用脂溶性β受体阻滞剂时有噩梦或幻觉病史的患者。所有接受脂溶性β受体阻滞剂治疗的患者均报告有噩梦或幻觉,但接受阿替洛尔治疗的患者中只有3人报告有此类情况。接受阿替洛尔治疗的患者(8次)发作总数显著低于接受脂溶性β受体阻滞剂治疗的患者(54次)(p<0.01)。结论是,与脂溶性β受体阻滞剂美托洛尔和普萘洛尔相比,阿替洛尔诱发噩梦和幻觉的可能性显著更低。这一发现似乎是由于这些药物亲水性的差异所致。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验